| Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12 … YK Kang, N Boku, T Satoh, MH Ryu, Y Chao, K Kato, HC Chung, JS Chen, ... The Lancet 390 (10111), 2461-2471, 2017 | 2070 | 2017 |
| Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer JN Kather, AT Pearson, N Halama, D Jäger, J Krause, SH Loosen, A Marx, ... Nature medicine 25 (7), 1054-1056, 2019 | 938 | 2019 |
| Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial K Fujitani, HK Yang, J Mizusawa, YW Kim, M Terashima, SU Han, ... The Lancet Oncology 17 (3), 309-318, 2016 | 701 | 2016 |
| Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer: Japan … H Katai, J Mizusawa, H Katayama, M Takagi, T Yoshikawa, T Fukagawa, ... Gastric Cancer 20, 699-708, 2017 | 391 | 2017 |
| Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG … H Katai, M Sasako, H Fukuda, K Nakamura, N Hiki, M Saka, H Yamaue, ... Gastric cancer 13, 238-244, 2010 | 370 | 2010 |
| Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma T Sano, M Sasako, J Mizusawa, S Yamamoto, H Katai, T Yoshikawa, ... Annals of surgery 265 (2), 277-283, 2017 | 350 | 2017 |
| Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial K Yoshida, Y Kodera, M Kochi, W Ichikawa, Y Kakeji, T Sano, N Nagao, ... Journal of Clinical Oncology 37 (15), 1296, 2019 | 321 | 2019 |
| Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer T Yoshikawa, M Sasako, S Yamamoto, T Sano, H Imamura, K Fujitani, ... Journal of British Surgery 96 (9), 1015-1022, 2009 | 295 | 2009 |
| Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer K Kato, K Chin, T Yoshikawa, K Yamaguchi, Y Tsuji, T Esaki, K Sakai, ... Investigational new drugs 30, 1621-1627, 2012 | 276 | 2012 |
| Is gastric carcinoma different between Japan and the United States? A comparison of patient survival among three institutions Y Noguchi, T Yoshikawa, A Tsuburaya, H Motohashi, MS Karpeh, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2000 | 266 | 2000 |
| Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a … H Katai, J Mizusawa, H Katayama, S Morita, T Yamada, E Bando, S Ito, ... The lancet Gastroenterology & hepatology 5 (2), 142-151, 2020 | 261 | 2020 |
| Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas SJ Lin, JA Gagnon-Bartsch, IB Tan, S Earle, L Ruff, K Pettinger, B Ylstra, ... Gut 64 (11), 1721-1731, 2015 | 231 | 2015 |
| Mapping of lymph node metastasis from esophagogastric junction tumors: a prospective nationwide multicenter study Y Kurokawa, H Takeuchi, Y Doki, S Mine, M Terashima, T Yasuda, ... Annals of surgery 274 (1), 120-127, 2021 | 200 | 2021 |
| Usefulness of enhanced recovery after surgery protocol as compared with conventional perioperative care in gastric surgery T Yamada, T Hayashi, H Cho, T Yoshikawa, H Taniguchi, R Fukushima, ... Gastric cancer 15, 34-41, 2012 | 195 | 2012 |
| A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data LT Chen, T Satoh, MH Ryu, Y Chao, K Kato, HC Chung, JS Chen, K Muro, ... Gastric cancer 23, 510-519, 2020 | 186 | 2020 |
| Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer T Aoyama, T Yoshikawa, J Shirai, T Hayashi, T Yamada, K Tsuchida, ... Annals of surgical oncology 20, 2000-2006, 2013 | 183 | 2013 |
| Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies S Hasegawa, T Yoshikawa Gastric cancer 13, 63-73, 2010 | 173 | 2010 |
| KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer YJ Bang, E Van Cutsem, CS Fuchs, A Ohtsu, J Tabernero, DH Ilson, ... Future Oncology 15 (9), 943-952, 2019 | 167 | 2019 |
| Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma T Yoshikawa, A Tsuburaya, O Kobayashi, M Sairenji, H Motohashi, ... Cancer letters 153 (1-2), 7-12, 2000 | 162 | 2000 |
| Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the … Japan Clinical Oncology Group (JCOG9502) Kurokawa Y Sasako M msasako@ hyo ... Journal of British Surgery 102 (4), 341-348, 2015 | 161 | 2015 |
Junki MizusawaJapan Clinical Oncology Group Data Center/National Cancer CenterVerified email at ncc.go.jp
